KZR — Kezar Life Sciences Balance Sheet
0.000.00%
- $46.57m
- -$46.35m
- 30
- 51
- 54
- 41
Annual balance sheet for Kezar Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 140 | 208 | 277 | 201 | 132 |
| Net Total Receivables | 0.766 | 0.07 | — | 2.29 | 0.424 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 145 | 212 | 286 | 207 | 137 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 6.75 | 6 | 13.2 | 8.69 | 4.78 |
| Other Long Term Assets | |||||
| Total Assets | 152 | 218 | 300 | 221 | 145 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 6.44 | 8.21 | 11 | 17.7 | 20.3 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 10.9 | 21.1 | 29.7 | 33.7 | 27.8 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 141 | 197 | 270 | 188 | 117 |
| Total Liabilities & Shareholders' Equity | 152 | 218 | 300 | 221 | 145 |
| Total Common Shares Outstanding |